MDL-27531

MDL-27531 acts functionally like a glycine agonist. MDL-27531 selectively reduces hindlimb contractions. MDL-27531 selectively reverses strychnine-induced seizures in mice. MDL-27531 inhibits pentylenetetrazol-induced seizures with an ED50 of 55 mg/kg. MDL-27531 promotes the binding of benzodiazepine antagonist Ro 15-1788 to cerebral cortex of mice without changing GABA levels. MDL-27531 can be studied in research on reflex control dysfunction[1][2].

Product Specifications

CAS Number

[116850-44-3]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Glycine Receptor (GlyR)

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

O=S(=O)(C1=NN=C(C=2C=CC=CC2)N1C)C

Molecular Formula

C10H11N3O2S

Molecular Weight

237.28

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Kehne, J. H., et al., (1992) . MDL 27,531 selectively reverses strychnine-induced seizures in mice. British journal of pharmacology, 106 (4), 910-916.|[2]Kehne, J. H., et al., (1992) . MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neuroscience letters, 147 (1), 101-105.